Jai-jen Tsai

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Molecular mechanisms and biomarkers of total parenteral nutrition-induced hepatotoxicity revealed by iTRAQ proteomics analysis.

Molecular mechanisms and biomarkers of total parenteral nutrition-induced hepatotoxicity revealed by iTRAQ proteomics analysis.

Journal: International journal of medical sciences

Published: July 19, 2025

In Reply to Yeh et al.

In Reply to Yeh et al.

Journal: International journal of radiation oncology, biology, physics

Published: March 04, 2023

Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.

Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.

Journal: International journal of radiation oncology, biology, physics

Published: May 03, 2022

Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.

Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.

Journal: Anticancer research

Published: February 26, 2022

DNA damage and NF-κB inactivation implicate glycyrrhizic acid-induced G1 phase arrest in hepatocellular carcinoma cells.

DNA damage and NF-κB inactivation implicate glycyrrhizic acid-induced G1 phase arrest in hepatocellular carcinoma cells.

Journal: Journal of food biochemistry

Published: September 12, 2021

Sorafenib Induces Apoptosis and Inhibits NF-κB-mediated Anti-apoptotic and Metastatic Potential in Osteosarcoma Cells.

Sorafenib Induces Apoptosis and Inhibits NF-κB-mediated Anti-apoptotic and Metastatic Potential in Osteosarcoma Cells.

Journal: Anticancer research

Published: January 19, 2021

Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.

Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 28, 2020

Apoptosis induction and ERK/NF-κB inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo.

Apoptosis induction and ERK/NF-κB inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo.

Journal: Environmental toxicology

Published: May 23, 2019

Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro.

Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro.

Journal: In vivo (Athens, Greece)

Published: February 06, 2018

Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.

Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.

Journal: Anticancer research

Published: December 29, 2017

Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.

Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.

Journal: Bioscience reports

Published: September 15, 2017

Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-κB Activation in Osteosarcoma U2OS Cells.

Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-κB Activation in Osteosarcoma U2OS Cells.

Journal: Anticancer research

Published: June 18, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026